| First Author | Sim JH | Year | 2014 |
| Journal | PLoS One | Volume | 9 |
| Issue | 7 | Pages | e101753 |
| PubMed ID | 25006961 | Mgi Jnum | J:218918 |
| Mgi Id | MGI:5619028 | Doi | 10.1371/journal.pone.0101753 |
| Citation | Sim JH, et al. (2014) Absence of PKC-alpha attenuates lithium-induced nephrogenic diabetes insipidus. PLoS One 9(7):e101753 |
| abstractText | Lithium, an effective antipsychotic, induces nephrogenic diabetes insipidus (NDI) in approximately 40% of patients. The decreased capacity to concentrate urine is likely due to lithium acutely disrupting the cAMP pathway and chronically reducing urea transporter (UT-A1) and water channel (AQP2) expression in the inner medulla. Targeting an alternative signaling pathway, such as PKC-mediated signaling, may be an effective method of treating lithium-induced polyuria. PKC-alpha null mice (PKCalpha KO) and strain-matched wild type (WT) controls were treated with lithium for 0, 3 or 5 days. WT mice had increased urine output and lowered urine osmolality after 3 and 5 days of treatment whereas PKCalpha KO mice had no change in urine output or concentration. Western blot analysis revealed that AQP2 expression in medullary tissues was lowered after 3 and 5 days in WT mice; however, AQP2 was unchanged in PKCalpha KO. Similar results were observed with UT-A1 expression. Animals were also treated with lithium for 6 weeks. Lithium-treated WT mice had 19-fold increased urine output whereas treated PKCalpha KO animals had a 4-fold increase in output. AQP2 and UT-A1 expression was lowered in 6 week lithium-treated WT animals whereas in treated PKCalpha KO mice, AQP2 was only reduced by 2-fold and UT-A1 expression was unaffected. Urinary sodium, potassium and calcium were elevated in lithium-fed WT but not in lithium-fed PKCalpha KO mice. Our data show that ablation of PKCalpha preserves AQP2 and UT-A1 protein expression and localization in lithium-induced NDI, and prevents the development of the severe polyuria associated with lithium therapy. |
